Headland Capital LLC Purchases 1,441 Shares of Boston Scientific Corporation $BSX

Headland Capital LLC lifted its position in Boston Scientific Corporation (NYSE:BSX) by 1.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,704 shares of the medical equipment provider’s stock after acquiring an additional 1,441 shares during the period. Boston Scientific accounts for 4.1% of Headland Capital LLC’s holdings, making the stock its 6th largest position. Headland Capital LLC’s holdings in Boston Scientific were worth $9,635,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. 1248 Management LLC acquired a new position in Boston Scientific during the first quarter worth $26,000. Y.D. More Investments Ltd acquired a new position in Boston Scientific during the first quarter worth $27,000. Sound Income Strategies LLC boosted its stake in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group acquired a new position in Boston Scientific during the second quarter worth $37,000. Finally, Activest Wealth Management boosted its stake in Boston Scientific by 6,216.7% during the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 373 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company’s stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of a number of recent research reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research note on Saturday, September 27th. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday. BTIG Research upped their price target on Boston Scientific from $127.00 to $132.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Finally, Barclays upped their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $120.79.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $97.30 on Monday. The stock’s 50-day moving average is $102.93 and its two-hundred day moving average is $102.06. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The company has a market cap of $144.17 billion, a price-to-earnings ratio of 57.91, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the business posted $0.62 EPS. The business’s revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.